Terms: = Liver cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Treatment
21959 results:
1. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract] [Full Text] [Related]
2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
3. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
[TBL] [Abstract] [Full Text] [Related]
6. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
Ooi SL; Micalos PS; Kim J; Pak SC
Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
[TBL] [Abstract] [Full Text] [Related]
7. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract] [Full Text] [Related]
8. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
9. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H; von Itzstein MS; Fattah F; Liu J; Zhu C; Xie Y; Wakeland EK; Park JY; Kahl BS; Diefenbach CS; Gerber DE
Oncoimmunology; 2024; 13(1):2351255. PubMed ID: 38737792
[TBL] [Abstract] [Full Text] [Related]
10. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from
Yang S; Chu G; Wu J; Zhang G; Du L; Lin R
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731467
[TBL] [Abstract] [Full Text] [Related]
11. Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.
Feldman TC; Kaplan DE; Lin A; La J; Lee JSH; Aljehani M; Tuck DP; Brophy MT; Fillmore NR; Do NV
JCO Clin Cancer Inform; 2024 May; 8():e2300159. PubMed ID: 38728613
[TBL] [Abstract] [Full Text] [Related]
12. Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report.
Huang H; Wei Q; Leng C; Wang H; Mei B
Medicine (Baltimore); 2024 May; 103(19):e38138. PubMed ID: 38728500
[TBL] [Abstract] [Full Text] [Related]
13. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
14. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract] [Full Text] [Related]
15. Novel Inositol 1,4,5-Trisphosphate Receptor Inhibitor Antagonizes Hepatic Stellate Cell Activation: A Potential Drug to Treat liver Fibrosis.
Smith-Cortinez N; Heegsma J; Podunavac M; Zakarian A; Cardenas JC; Faber KN
Cells; 2024 Apr; 13(9):. PubMed ID: 38727301
[TBL] [Abstract] [Full Text] [Related]
16. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
Shindo T; Hashimoto K; Fujino K; Takahashi A; Hotta H; Maeda T; Kunishima Y; Fukuta F; Ito N; Wanifuchi A; Kato R; Okada M; Matsukawa M; Horita H; Takayanagi A; Kobayashi K; Tanaka T; Masumori N
World J Urol; 2024 May; 42(1):307. PubMed ID: 38722418
[TBL] [Abstract] [Full Text] [Related]
17. Malnutrition as an unfavorable prognostic factor after surgical treatment for metastatic colorectal cancer.
Skroński M; Olszewska N; Nyckowski P; Ukleja A; Lisowska J; Słodkowski M; Szczygieł B
Pol Przegl Chir; 2024 Mar; 96(3):1-8. PubMed ID: 38721641
[TBL] [Abstract] [Full Text] [Related]
18. Preoperative three-dimensional lung volumetry predicts respiratory complications in patients undergoing major liver resection for colorectal metastases.
Elmaagacli S; Thiele C; Meister F; Menne P; Truhn D; Olde Damink SWM; Bickenbach J; Neumann U; Lang SA; Vondran F; Amygdalos I
Sci Rep; 2024 May; 14(1):10594. PubMed ID: 38719953
[TBL] [Abstract] [Full Text] [Related]
19. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
[TBL] [Abstract] [Full Text] [Related]
20. Laparoscopic-assisted microwave ablation in treatment of small hepatocellular carcinoma: safety and efficacy in comparison with laparoscopic hepatectomy.
Wei Y; Zhang L; Zhang S; Song M; Ji C
BMC Surg; 2024 May; 24(1):138. PubMed ID: 38715071
[TBL] [Abstract] [Full Text] [Related]
[Next]